List of withdrawn drugs

Template:Short description {{ safesubst:#invoke:Unsubst||date=__DATE__ |$B=Template:AmboxTemplate:Main other }} Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs) or because it turns out that they are less effective in clinical practice than premarketing efficacy trials suggested. When risks or harms are the cause, withdrawals will usually have been prompted by unexpected adverse effects that were not detected during the early, premaketing, clinical trials, i.e. they became apparent only from postmarketing surveillance data collected from the wider community during routine use over longer periods of time.

This list is not limited to drugs that were ever approved by specific jurisdictions. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran, and zimeldine, for example) received marketing approval in Europe but had not yet been approved for marketing in the United States when adverse effects became clear and they were withdrawn from the market. Some drugs in this list (e.g. LSD) were never approved for marketing in the United States or Europe.

Significant withdrawals

Drug name (INNs where available)	Withdrawn	Country	Remarks
Amphetamine - mixture of four salts (Adderall XR)	2005	Canada	Withdrawn after reports of increased risk of stroke; reinstated after increased risk not found<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Alatrofloxacin	2006	Worldwide	Serious hepatotoxicity leading to liver transplant or death<ref name=Qureshi-2011 />
Alclofenac	1979	UK	Vasculitis<ref name=Fung-2001>Template:Cite journal</ref>
Alpidem (Ananxyl)	1995	Worldwide	citation	CitationClass=web }}</ref> and the rest of the world in 1995 because of rare but serious hepatotoxicity<ref name=Fung-2001 /><ref>Template:Cite journal</ref>
Alosetron (Lotronex)	2000	US	Serious gastrointestinal adverse events; ischaemic colitis; severe constipation;<ref name=Qureshi-2011 /> reintroduced in 2002 with restricted indications and new controls<ref>Template:Cite news</ref>
Alphaxolone/Alphadolone (Althesin)	1984	France, Germany, UK	Anaphylaxis, possibly due to the carrier oil (Cremophor EL)<ref name="Fung-2001" />
Amineptine (Survector)	1999	France, US	Hepatotoxicity, dermatological adverse effects, and abuse potential<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Aminophenazone (aminopyrine)	1999	France, Thailand	Risk of agranulocytosis and severe acne<ref name=Fung-2001 />
Amobarbital	1980	Norway	Risk of barbiturate toxicity<ref name=Fung-2001 />
Amoproxan	1970	France	Dermatological and ophthalmic toxicity<ref name=Fung-2001 />
Anagestone acetate	1969	Germany	Animal carcinogenicity<ref name=Fung-2001 />
Antrafenine	1984	France	Unspecific experimental toxicity<ref name=Fung-2001 />
Aprotinin (Trasylol)	2008	US	Increased risk of death<ref name=Qureshi-2011 />
Ardeparin (Normiflo)	2001	US	Withdrawn at the request of the NDA originator, "not for reason of safety or efficacy"<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Astemizole (Hismanal)	1999	US, Malaysia, several nonspecified markets	Fatal arrhythmia<ref name=Qureshi-2011 /><ref name=Fung-2001 />
Azaribine	1976	US	Thromboembolism<ref name=Fung-2001 />
Bendazac	1993	Spain	Hepatotoxicity<ref name="Fung-2001" />
Benoxaprofen (Oraflex, Opren)	1982	Germany, Spain, UK, US	Liver and kidney failure; gastrointestinal bleeding; ulcers<ref name="Qureshi-2011">Template:Cite journal</ref><ref name="Fung-2001" />
Benzarone	1992	Germany	Hepatitis<ref name="Fung-2001" />
Benziodarone	1964	France, UK	Jaundice<ref name="Fung-2001" />
Beta-ethoxy-acetanilanide	1986	Germany	Renal toxicity, animal carcinogenicity<ref name="Fung-2001" />
Bezitramide	2004	Netherlands	citation	CitationClass=web }}</ref>
Bithionol	1967	US	Dermatological toxicity<ref name="Fung-2001" />
Brotizolam	1989	UK	Animal carcinogenicity<ref name="Fung-2001" />
Bromfenac	1998	US	Severe hepatitis and liver failure (requiring transplantation)<ref name="Qureshi-2011" />
Bucetin	1986	Germany	Kidney damage<ref name="Fung-2001" />
Buformin	1978	Germany	Metabolic toxicity<ref name="Fung-2001" />
Bunamiodyl	1963	Canada, UK, US	citation	CitationClass=web }}</ref>
Butamben (Efocaine)(Butoforme)	1964	US	Dermatological toxicity; psychiatric reactions<ref name="Fung-2001" />
Canrenone	1986	Germany	Animal carcinogenicity<ref name="Fung-2001" />
Cerivastatin (Baycol, Lipobay)	2001	US	Risk of rhabdomyolysis<ref name="Qureshi-2011" />
Chlormadinone (Chlormenadione)	1970	UK, US	Animal carcinogenicity<ref name="Fung-2001" />
Chlormezanone (Trancopal)	1996	European Union, US, South Africa, Japan	Hepatotoxicity and Stevens–Johnson Syndrome<ref name="Fung-2001" />
Chlorphentermine	1969	Germany	Cardiovascular toxicity<ref name="Fung-2001" />
Cianidanol	1985	France, Germany, Spain, Sweden	Haemolytic anaemia<ref name="Fung-2001" />
Cinepazide	1988	Spain	Agranulocytosis<ref name="WHO2005">WHO. Consolidated List of Products – Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments, Twelfth Issue – Pharmaceuticals Template:Webarchive. United Nations – New York, 2005</ref><ref>Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals Template:Webarchive United Nations – New York, 2005</ref>
Cisapride (Propulsid)	2000	US	Risk of fatal cardiac arrhythmias<ref name="Qureshi-2011" />
Clioquinol	1973	France, Germany, UK, US	Neurotoxicity<ref name="Fung-2001" />
Clobutinol	2007	Germany	Ventricular arrhythmias, QT-interval prolongation<ref name=Schubert-Zsilavecz>Template:Cite news</ref>
Cloforex	1969	Germany	Cardiovascular toxicity<ref name="Fung-2001" />
Clomacron	1982	UK	Hepatotoxicity<ref name="Fung-2001" />
Clometacin	1987	France	Hepatotoxicity<ref name="Fung-2001" />
Co-proxamol (codeine + paracetamol; Distalgesic)	2004	UK	Risk of overdose
Cyclobarbital	1980	Norway	Risk of overdose<ref name="Fung-2001" />
Cyclofenil	1987	France	Hepatotoxicity<ref name="Fung-2001" />
Dantron	1963	Canada, UK, US	Mutagenic;<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref> withdrawn from general use in the UK but permitted in terminal patients
Dexfenfluramine	1997	European Union, UK, US	Cardiotoxic<ref name="Fung-2001" />
Propoxyphene (Darvocet/Darvon)	2010	Worldwide	citation	CitationClass=web }}</ref>
Diacetoxydiphenolisatin	1971	Australia	Hepatotoxicity<ref name="Fung-2001" />
Diethylstilbestrol	1970s	US	Carcinogen
Difemerine	1986	Germany	Multi-organ toxicities<ref name="Fung-2001" />
Dihydrostreptomycin	1970	US	Neuropsychiatric reactions<ref name="Fung-2001" />
Dilevalol	1990	UK	Hepatotoxicity<ref name="Fung-2001" />
Dimazole (Diamthazole)	1972	France, US	Neuropsychiatric reactions<ref name="Fung-2001" />
Dimethylamylamine (DMAA)	1983	US	Voluntarily withdrawn from market by Lilly;<ref name=DODTox>Col John Lammie et al. Report of the Department Of Defense: 1,3 Dimethylamylamine (Dmaa) Safety Review Panel Template:Webarchive June 3, 2013</ref>Template:Rp reintroduced as a dietary supplement in 2006;<ref name=DODTox/>Template:Rp in 2013 the FDA started work to ban it because of cardiovascular problems<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Dinoprostone	1990	UK	Uterine hypotonus, fetal distress<ref name="Fung-2001" />
Dipyrone (Metamizole)	1975	UK, US, others	Agranulocytosis, anaphylactic reactions<ref name="Fung-2001" />
Dithiazanine iodide	1964	France, US	Cardiovascular and metabolic reactions<ref name="Fung-2001" />
Dofetilide	2004	Germany	Drug-drug interactions, prolonged QT<ref name=Schubert-Zsilavecz />
Drotrecogin alfa (Xigris)	2011	Worldwide	Lack of efficacy as shown in the PROWESS-SHOCK study<ref>Drotrecogin Alfa (Activated) in Adults with Septic Shock Template:Webarchive, N Engl J Med 2012; 366:2055–2064, May 31, 2012, {{#invoke:CS1 identifiers|main|_template=doi}}</ref><ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Ebrotidine	1998	Spain	Hepatotoxicity<ref name="Fung-2001" />
Efalizumab (Raptiva)	2009	Germany	Increased risk of progressive multifocal leukoencephalopathy<ref name=Schubert-Zsilavecz />
Encainide	1991	UK, US	Ventricular arrhythmias<ref name="Qureshi-2011" /><ref name="Fung-2001" />
Ethyl carbamate	1963	Canada, UK, US	citation	CitationClass=web }}</ref>
Etretinate	1989	France	Teratogen<ref name="Qureshi-2011" /><ref name="Fung-2001" />
Exifone	1989	France	Hepatotoxicity<ref name="Fung-2001" />
Fen-phen (combination of fenfluramine + phentermine)	1997		Cardiotoxicity
Fenclofenac	1984	UK	Cutaneous reactions; animal carcinogenicity<ref name="Fung-2001" />
Fenclozic acid	1970	UK, US	Hepatotoxicity<ref name="Fung-2001" />
Fenfluramine	1997	European Union, UK, US, India, South Africa, others	citation	CitationClass=web }}</ref> re-approved in June 2020 for treatment of seizures associated with Dravet syndrome, under FDA orphan drug rules
Fenoterol	1990	New Zealand	Increased asthma mortality<ref name="Fung-2001" />
Feprazone	1984	Germany, UK	Cutaneous reactions, multiorgan toxicity<ref name="Fung-2001" />
Fipexide	1991	France	Hepatotoxicity<ref name="Fung-2001" />
Flosequinan (Manoplax)	1993	UK, US	Increased mortality at higher doses; increased hospitalizations<ref name="Qureshi-2011" /><ref name="Fung-2001" />
Flunitrazepam	1991	France	Abuse<ref name="Fung-2001" />
Flupirtine	2018	European Union	citation	CitationClass=web }}</ref>
Gatifloxacin	2006	US	Increased risk of dysglycaemia<ref name=Qureshi-2011 />
Gemtuzumab ozogamicin (Mylotarg)	2010	US	citation	CitationClass=web }}</ref>
Glafenine	1984	France, Germany	Anaphylaxis<ref name=Fung-2001 />
Grepafloxacin (Raxar)	1999	Germany, UK, US, others	Cardiac repolarization; QT interval prolongation<ref name=Qureshi-2011 />
Hydromorphone (Palladone, extended release version)	2005		High risk of accidental overdose when extended release version (Palladone) administered with alcohol; standard hydromorphone is sold in most of the world, including the US
Ibufenac	1968	UK	Hepatotoxicity, jaundice<ref name=Fung-2001 />
Indalpine	1985	France	Agranulocytosis<ref name=Fung-2001 />
Indoprofen	1983	Germany, Spain, UK	Animal carcinogenicity, gastrointestinal toxicity<ref name=Fung-2001 />
Ingenol mebutate gel	2020	Suspended in Europe	citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Iodinated casein strophantin	1964	US	Metabolic reactions<ref name=Fung-2001 />
Iproniazid	1964	Canada	citation	CitationClass=web }}</ref>
Isaxonine phosphate	1984	France	Hepatotoxicity<ref name=Fung-2001 />
Isoxicam	1983	France, Germany, Spain, others	Stevens–Johnson syndrome<ref name=Fung-2001 />
Kava kava (Piper methysticum)	2002	Germany	Hepatotoxicity<ref name=Schubert-Zsilavecz />
Ketorolac	1993	France, Germany, others	Haemorrhage, Kidney Failure<ref name=Fung-2001 />
L-tryptophan	1989	Germany, UK	Eosinophilic myalgia syndrome;<ref name=Fung-2001 /> still sold in the US
Levamisole (Ergamisol)	1999	US	Still used as veterinary drug and as a human antihelminthic in many markets; listed on the WHO's List of Essential Medicines; in humans, it was used to treat melanoma before it was withdrawn because of agranulocytosis<ref name="mmwr">Template:Cite journal</ref><ref name="annals">Template:Cite journal</ref><ref>Template:Cite journal</ref>
Levomethadyl acetate	2003	US	Cardiac arrhythmias and cardiac arrest<ref name=Qureshi-2011 />
Lorcaserin (Belviq)	2020	US	Increased risk of cancer<ref>Template:Cite journal</ref>
Lumiracoxib (Prexige)	2007–2008	Worldwide	Liver damage
Lysergic acid diethylamide (LSD)	1950s–1960s		Marketed as a psychiatric drug; withdrawn after it became widely used recreationally; now illegal in most of the world
Mebanazine	1975	UK	Hepatotoxicity, drug-drug interactions<ref name=Fung-2001 />
Methandrostenolone	1982	France, Germany, UK, US, others	Off-label abuse<ref name=Fung-2001 />
Methapyrilene	1979	Germany, UK, US	Animal carcinogenicity<ref name=Fung-2001 />
Methaqualone	1984	South Africa (1971), India (1984), United Nations (1971–1988)	Withdrawn because of risk of addiction and overdose<ref name=CDSCO-India>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref><ref name=SAPS-Methaqualone>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Metipranolol	1990	UK, others	Uveitis<ref name=Fung-2001 />
Metofoline	1965	US	Unspecific experimental toxicity<ref name=Fung-2001 />
Mibefradil	1998	European Union, Malaysia, US, others	Fatal arrhythmias, drug-drug interactions<ref name="Qureshi-2011" /><ref name=Fung-2001 />
Minaprine	1996	France	Convulsions<ref name=Fung-2001 />
Moxisylyte	1993	France	Necrotic hepatitis<ref name=Fung-2001 />
Muzolimine	1987	France, Germany, European Union	Polyneuropathy<ref name=Fung-2001 />
Natalizumab (Tysabri)	2005–2006	US	Voluntarily withdrawn from the US market because of a risk of Progressive multifocal leukoencephalopathy (PML); returned to the market in July 2006
Nefazodone	2004	Europe, Australia, New Zealand, Canada<ref>Template:Cite news</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>	Branded version withdrawn by the originator in several countries in 2007 because of hepatotoxicity; generic versions available; still available in the US
Nialamide	1974	UK, US	Hepatotoxicity, drug -drug interactions<ref name=Fung-2001 />
Nikethamide	1988	Multiple markets	CNS stimulation<ref name=Fung-2001 />
Nitrefazole	1984	Germany	Hepatic and haematological toxicity<ref name=Fung-2001 />
Nomifensine	1981–1986	France, Germany, Spain, UK, US, others	Haemolytic anaemia, hepatotoxicity, serious hypersensitivity reactions<ref name="Qureshi-2011" /><ref name=Fung-2001 />
Oxeladin	1976	Canada, UK, US (1976)	citation	CitationClass=web }}</ref>
Oxyphenbutazone	1984–1985	UK, US, Germany, France, Canada	Bone marrow suppression, Stevens–Johnson syndrome<ref name=Fung-2001 /><ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref><ref>Template:Cite journal</ref>
Oxyphenisatin (Phenisatin)	1970s	Australia, France, Germany, UK, US	Hepatotoxicity<ref name=Fung-2001 />
Ozogamicin	2010	US	No improvement in clinical benefit; risk of death; veno-occlusive disease<ref name="Qureshi-2011" />
Pemoline (Cylert)	1997	Canada, UK	citation	CitationClass=web }}</ref><ref name=Fung-2001 />
Pentobarbital	1980	Norway	Risk of fatal overdose<ref name=Fung-2001 />
Pentylenetetrazol	1982	US	Withdrawn because of inability to produce effective convulsive therapy, and because it caused seizures
Pergolide (Permax)	2007	US	Risk of heart valve damage<ref name="Qureshi-2011" />
Perhexiline	1985	UK, Spain	Neurological and hepatic toxicity<ref name=Fung-2001 />
Phenacetin	1975	Canada	citation	CitationClass=web }}</ref> in Germany, Denmark, UK, US, and in others because of nephropathy<ref name=Fung-2001 />
Phenformin and Buformin	1977	France, Germany, US	Severe lactic acidosis<ref name=Fung-2001 />
Phenolphthalein	1997	US	Possible carcinogen<ref name=Wysowski-2005>Template:Cite journal</ref>
Phenoxypropazine	1966	UK	Hepatotoxicity, drug-drug intereactions<ref name=Fung-2001 />
Phenylbutazone	1985	Germany	Off-label abuse, haematological toxicity<ref name=Fung-2001 />
Phenylpropanolamine (Propagest, Dexatrim)	2000	Canada, US	citation	CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Pifoxime (=Pixifenide)	1976	France	Neuropsychiatric reactions<ref name=Fung-2001 />
Pirprofen	1990	France, Germany, Spain	Liver toxicity.<ref name=Fung-2001 /><ref name="WHO2005"/>Template:Rp
Prenylamine	1988	Canada, France, Germany, UK, US, others	citation	CitationClass=web }}</ref> and death<ref name=Fung-2001 />
Proglumide	1989	Germany	Respiratory reactions<ref name=Fung-2001 />
Pronethalol	1965	UK	Animal carcinogenicity<ref name=Fung-2001 />
Propanidid	1983	UK	Allergy<ref name=Fung-2001 />
Proxibarbal	1998	Spain, France, Italy, Portugal, Turkey	Immunoallergic, thrombocytopenia<ref name=Fung-2001 />
Pyrovalerone	1979	France	Abuse<ref name=Fung-2001 />
Ranitidine (Zantac)	2020	Worldwide	Found to spontaneously break down into the carcinogen N-nitrosodimethylamine
Rapacuronium (Raplon)	2001	US, multiple markets	Withdrawn in many countries because of the risk of fatal bronchospasm<ref name="Qureshi-2011" />
Remoxipride	1993	UK, others	Aplastic anaemia<ref name=Fung-2001 />
Rhesus rotavirus vaccine-tetravalent (RotaShield)	1999	US	Withdrawn because of a risk of intussusception<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Rimonabant (Acomplia)	2008	Worldwide	Risk of severe depression and suicide<ref name=Schubert-Zsilavecz />
Rofecoxib (Vioxx)	2004	Worldwide	Withdrawn by Merck & Co. because of the risks of myocardial infarction and stroke<ref name="Qureshi-2011" />
Rosiglitazone (Avandia)	2010	Europe	Risk of heart attacks and death; still available in the US
Secobarbital	1990	France, Norway, othersTemplate:Which	Risk of overdose<ref name=Fung-2001 />
Sertindole	1998	European Union	citation	CitationClass=web }}</ref>
Sibutramine (Reductil/Meridia)	2010	citation	CitationClass=web }}</ref> Canada,<ref>Health Canada Endorsed Important Safety Information on MERIDIA (Sibutramine Hydrochloride Monohydrate) Template:Webarchive: Subject: Voluntary withdrawal of Meridia (sibutramine) capsules from the Canadian market.</ref> China,<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref> the European Union (EU),<ref>Template:In lang Sibutramin-Vertrieb in der Europäischen Union ausgesetzt [1]. Abbott Laboratories in Germany. Press Release 2010-01-21. Retrieved 2010-01-27</ref> Hong Kong,<ref>Template:Cite press release</ref> India,<ref>Template:Cite press release</ref> Mexico, New Zealand,<ref>Template:Cite press release</ref> the Philippines,<ref>Template:Cite news</ref> Thailand,<ref>Template:Cite press release</ref> the United Kingdom,<ref>Template:Cite news</ref> US<ref name="wsj">Template:Cite news</ref>	Increased risk of heart attack and stroke<ref name="Qureshi-2011" />
Sitaxentan	2010	Germany	Hepatotoxicity<ref name=Schubert-Zsilavecz />
Sorivudine	1993	Japan	Drug-drug interactions and deaths<ref>H. Gurdon: Japan bans shingles drug after deaths Template:Webarchive BMJ 1994;309:627</ref>
Sparfloxacin	2001	US	QT interval prolongation and phototoxicity<ref name="Qureshi-2011" />
Sulfacarbamide	1988	Germany	Dermatological, hematological, and hepatic reactions<ref name=Fung-2001 />
Sulfamethoxydiazine	1988	Germany	Dermatological reactions
Sulfamethoxypyridazine	1986	UK	Dermatological and haematological reactions<ref name=Fung-2001 />
Suloctidil	1985	Germany, France, Spain	Hepatotoxicity<ref name=Fung-2001 />
Suprofen	1986–1987	UK, Spain, US	Kidney damage<ref name="Qureshi-2011" /><ref name=Fung-2001 />
Tegaserod (Zelnorm)	2007	US	Risks of heart attack, stroke, and unstable angina;<ref name="Qureshi-2011" /> was available through a restricted access programme until April 2008; returned to the market in 2019
Temafloxacin	1992	Germany, UK, US, others	Low blood sugar; haemolytic anaemia; kidney, liver dysfunction; allergic reactions<ref name="Qureshi-2011" /><ref name=Fung-2001 />
Temafloxacin	1992	US	Allergic reactions and cases of haemolytic anaemia, leading to three deaths[2]
Temazepam (Restoril, Euhypnos, Normison, Remestan, Tenox, Norkotral)	1999	Sweden, Norway	Diversion, abuse, and a relatively high rate of overdose deaths compared with other drugs of its group; it is still available in most of the world, including the US, but under strict controls
Terfenadine (Seldane, Triludan)	1997–1998	France, South Africa, Oman, US, others	Prolonged QT interval; ventricular tachycardia<ref name="Qureshi-2011" /><ref name=Fung-2001 />
Terodiline (Micturin)	1991	Germany, UK, Spain, others	Prolonged QT interval, ventricular tachycardia, and other arrhythmias<ref name=Fung-2001 />
Tetrazepam	2013	European Union	citation	CitationClass=web }}</ref>
Thalidomide	1961	Germany	Withdrawn because of risk of teratogenicity;<ref>Template:Cite news</ref> returned to the market for use in leprosy and multiple myeloma under FDA orphan drug rules
Thenalidine	1963	Canada, UK, US	citation	CitationClass=web }}</ref>
Thiobutabarbital	1993	Germany	Kidney damage<ref name=Fung-2001 />
Thioridazine (Melleril)	2005	Germany, UK	Withdrawn worldwide because of severe cardiac arrhythmias;<ref name=PDS2012>Template:Cite journal</ref><ref name=NHS>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref> still available in Russia
Ticrynafen (Tienilic acid)	1980	Germany, France, UK, US, others	Liver toxicity and death<ref name=Fung-2001 />
Tolcapone (Tasmar)	1998	European Union, Canada, Australia	Hepatotoxicity<ref name=Fung-2001 />
Tolrestat (Alredase)	1996	Argentina, Canada, Italy, others	Severe hepatotoxicity<ref name=Fung-2001 />
Triacetyldiphenolisatin	1971	Australia	Hepatotoxicity<ref name=Fung-2001 />
Triazolam	1991	France, Netherlands, Finland, Argentina, UK, others	citation	CitationClass=web }}</ref>
Triparanol	1962	France, US	Cataracts, alopecia, ichthyosis<ref name=Fung-2001 />
Troglitazone (Rezulin)	2000	Germany, US	Hepatotoxicity<ref name="Qureshi-2011" />
Trovafloxacin (Trovan)	1999–2001	European Union, US	Withdrawn because of risk of liver failure<ref name="Qureshi-2011" /><ref name=Fung-2001 />
Valdecoxib (Bextra)	2004	US	Risk of heart attack and stroke<ref name="Qureshi-2011" />
Vincamine	1987	Germany	Haematological toxicity<ref name=Fung-2001 />
Xenazoic acid	1965	France	Hepatotoxicity<ref name=Fung-2001 />
Ximelagatran (Exanta)	2006	Germany	Hepatotoxicity<ref name=Schubert-Zsilavecz />
Zimeldine	1983	Worldwide	Risk of Guillain–Barré syndrome, hypersensitivity reactions, hepatotoxicity;<ref name=Fung-2001 /><ref name="Fagius">Template:Cite journal</ref><ref>Pubchem record says "withdrawn in 1983"</ref> banned worldwide.<ref>{{#invoke:citation/CS1|citation	CitationClass=web }}</ref>
Zomepirac	1983	UK, Germany, Spain, US	Anaphylactic reactions and non-fatal allergic reactions; kidney failure<ref name="Qureshi-2011" /><ref name=Fung-2001 />

See also

• Adverse drug reaction
• Adverse events
• European Medicines Agency
• Food and Drug Administration

External links

• CDER Report to the Nation: 2005 Has a list of US withdrawals through 2005.